CL2019003283A1 - Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas. - Google Patents

Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas.

Info

Publication number
CL2019003283A1
CL2019003283A1 CL2019003283A CL2019003283A CL2019003283A1 CL 2019003283 A1 CL2019003283 A1 CL 2019003283A1 CL 2019003283 A CL2019003283 A CL 2019003283A CL 2019003283 A CL2019003283 A CL 2019003283A CL 2019003283 A1 CL2019003283 A1 CL 2019003283A1
Authority
CL
Chile
Prior art keywords
antimitoskines
stem cells
properties
cancer stem
antimitoscines
Prior art date
Application number
CL2019003283A
Other languages
English (en)
Inventor
Federica Sotgia
Michael P Lisanti
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of CL2019003283A1 publication Critical patent/CL2019003283A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

LOS ANTIBIÓTICOS QUE TIENEN PROPIEDADES ANTIMITOCONDRIALES INTRÍNSECAS SE PUEDEN MODIFICAR QUÍMICAMENTE PARA DIRIGIR LOS ANTIBIÓTICOS A LAS MITOCONDRIAS, Y LAS "ANTIMITOSCINAS" RESULTANTES PUEDEN TENER PROPIEDADES ANTICANCEROSAS MEJORADAS, ENTRE OTRAS PROPIEDADES VENTAJOSAS. TAMBIÉN SE DESCRIBEN MÉTODOS PARA IDENTIFICAR ANTIMITOSCINAS, MÉTODOS PARA USAR ANTIMITOSCINAS PARA FIJAR COMO OBJETIVO CÉLULAS MADRE CANCEROSAS Y COMPOSICIONES FARMACÉUTICAS PARA TRATAR EL CÁNCER QUE CONTIENEN UNA O MÁS ANTIMITOSCINAS COMO EL INGREDIENTE ACTIVO. TAMBIÉN SE DAN A CONOCER COMPUESTOS ESPECÍFICOS DE ANTIMITOSCINAS Y GRUPOS DE ANTIMITOSCINAS.
CL2019003283A 2017-05-19 2019-11-15 Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas. CL2019003283A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508702P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
CL2019003283A1 true CL2019003283A1 (es) 2020-05-04

Family

ID=64274780

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003283A CL2019003283A1 (es) 2017-05-19 2019-11-15 Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas.

Country Status (20)

Country Link
US (2) US11160821B2 (es)
EP (1) EP3624840A4 (es)
JP (1) JP6938682B2 (es)
KR (1) KR20200010343A (es)
CN (1) CN111315400A (es)
AU (1) AU2018270129B2 (es)
BR (1) BR112019024264A2 (es)
CA (1) CA3063717C (es)
CL (1) CL2019003283A1 (es)
CO (1) CO2019012888A2 (es)
CR (1) CR20190524A (es)
CU (1) CU20190092A7 (es)
DO (1) DOP2019000294A (es)
EC (1) ECSP19082194A (es)
IL (1) IL270598B (es)
MX (1) MX2019013735A (es)
PE (1) PE20200605A1 (es)
RU (1) RU2019142102A (es)
WO (1) WO2018213751A1 (es)
ZA (3) ZA201907654B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018195446A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
RU2019142102A (ru) 2017-05-19 2021-06-21 Лунелла Байотек, Инк. Антимитосцины: направленные ингибиторы митохондриального биогенеза для эрадикации злокачественных стволовых клеток
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CN110913854B (zh) 2017-06-26 2023-04-28 卢内拉生物技术有限公司 mitoketoscin：靶向癌细胞中酮代谢的基于线粒体的治疗剂
EP3695005B1 (en) 2017-10-11 2023-12-06 Lunella Biotech, Inc. Anti-mitochondrial inhibitors for oncogenic ras and myc
EP3717015A4 (en) * 2017-12-01 2021-07-28 Lunella Biotech, Inc. REPURPOSCINS: TARGET MITOCHONDRIAL BIOGENESIS INHIBITORS TO ERADICATE CARCINOUS STEM CELLS
CA3114888A1 (en) 2018-10-02 2020-04-09 Lunella Biotech, Inc. Azithromycin and roxithromycin derivatives as senolytic drugs
BR112021011964A2 (pt) 2018-12-17 2021-09-08 Lunella Biotech, Inc. Terapias de combinação tripla para antienvelhecimento
AU2019403048A1 (en) * 2018-12-17 2021-07-08 Lunella Biotech, Inc. Triple combination therapies for targeting mitochondria and killing cancer stem cells
EP3976197A4 (en) * 2019-05-24 2023-07-19 Lunella Biotech, Inc. THERAPEUTIC AGENTS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER
CA3144666A1 (en) * 2019-06-26 2020-12-30 Lunella Biotech, Inc. Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells
EP4048246A4 (en) * 2019-10-24 2023-01-25 The Medical College of Wisconsin, Inc. MITOCHONDRIA-TARGETED ATOVAQUONE: A MORE POTENT AND EFFECTIVE ANTITUMOR, ANTIMICROBIAL AND ANTIMALARIAL DRUG
WO2021229499A1 (en) * 2020-05-13 2021-11-18 Lunella Biotech, Inc. Myristoyl derivatives of 9-amino-doxycycline for targeting cancer stem cells and preventing metastasis
CN116437922A (zh) * 2020-10-22 2023-07-14 卢内拉生物技术有限公司 预防转移的靶向γ亚单位的线粒体ATP抑制剂

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862921A (en) * 1953-08-13 1958-12-02 Upjohn Co Erythromycin esters
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DK149776C (da) * 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0656422B1 (en) 1993-11-05 2000-04-26 Amersham Pharmacia Biotech UK Limited Chloramphenicol acetyl transferase (CAT) assay
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
CA2189001A1 (en) 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
US6165999A (en) 1995-05-03 2000-12-26 Pfizer Inc Tetracycline derivatives
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
ATE296305T1 (de) 1997-11-25 2005-06-15 Antipodean Biotechnology Ltd Antioxidantien mit spezifischer wirkung auf mitochondrien
EP0941998B1 (en) 1998-03-03 2004-09-01 Pfizer Products Inc. 3,6-ketal macrolide antibiotics
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7169814B2 (en) * 2001-12-11 2007-01-30 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
US7485298B2 (en) 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
RU2223103C1 (ru) 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
WO2005062851A2 (en) 2003-12-22 2005-07-14 Pappolla Miguel A Indole-3-propionamide and derivatives thereof
JP2005200419A (ja) 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
JP2007523912A (ja) 2004-02-26 2007-08-23 アドバンスト アキュラー システムズ リミテッド 眼病変治療用へパリン
US20060083727A1 (en) 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
ES2371931T3 (es) 2005-01-14 2012-01-11 Glaxo Group Limited Compuestos macrólidos que contienen biotina y grupo con foto-afinidad para la identificación de la diana del macrólido.
CN1706391A (zh) 2005-05-09 2005-12-14 史同瑞 土霉素混悬乳剂
JP5177429B2 (ja) 2005-07-18 2013-04-03 バイパー サイエンシズ，インコーポレイティド 癌の治療
CN1837229A (zh) 2005-08-05 2006-09-27 济南思创生物技术有限公司 克拉霉素衍生物及其制备方法和药物应用
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
CN1837225A (zh) 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
WO2007139930A2 (en) 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
US20090311249A1 (en) 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
EP2526969A1 (en) 2006-09-07 2012-11-28 Stemline Therapeutics, Inc. Monitoring cancer stem cells
CN101631799A (zh) 2006-10-30 2010-01-20 南方研究院 靶向nbs1-atm相互作用以使癌细胞对放射疗法及化学疗法敏感
SI2117520T1 (sl) 2006-12-14 2019-01-31 Abraxis Bioscience, Llc Zdravljenje raka dojk glede na status hormonskih receptorjev z nano delci, ki zajemajo taksan
US8075902B2 (en) 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung
US20090099062A1 (en) 2007-05-31 2009-04-16 Ethan Lee Pyrvinium For The Treatment of Cancer
WO2009015214A2 (en) 2007-07-24 2009-01-29 Wayne State University Nanoparticles for imaging and treating chlamydial infection
EP2200653A2 (en) * 2007-09-10 2010-06-30 University of Massachusetts Mitochondria-targeted anti-tumour agents
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
AU2008307544A1 (en) 2007-10-02 2009-04-09 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
WO2010121177A2 (en) 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
GB0912584D0 (en) 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
JP2013503171A (ja) 2009-08-25 2013-01-31 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ がんの処置および予防におけるメトホルミンの使用
DK2338476T3 (da) * 2009-12-02 2012-09-17 Bettina Heil Suppositorium til rektal, vaginal eller urethral indgivelse indeholdende et probiotikum, et antibiotikum og en umættet ikke-forestret fedtsyre
SI2506840T1 (sl) 2009-12-04 2021-08-31 OncoC4, Inc. Uporabe zaviralcev faktorja, ki jih inducira hiposkija
EP2544692A4 (en) 2010-03-10 2013-08-07 Univ Health Network USE OF TIGECYCLINE FOR THE TREATMENT OF CANCER
CN101810570B (zh) * 2010-04-16 2012-06-20 成都师创生物医药科技有限公司 蒽环类抗肿瘤抗生素脂肪酸复合物脂质纳米粒制剂及其制备方法
US20110268722A1 (en) * 2010-04-22 2011-11-03 Siegelin Markus D Combination therapies with mitochondrial-targeted anti-tumor agents
US20120141467A1 (en) 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
WO2012107579A1 (en) 2011-02-10 2012-08-16 Ruprecht-Karls-Universität Heidelberg Hydrophobic modified peptides and their use for liver specific targeting
BR112013033239A2 (pt) 2011-06-22 2016-09-06 Vyome Biosciences pró-farmácos de conjugado baseado em atifungicos e antibacterianos
WO2013007708A1 (en) 2011-07-08 2013-01-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
CN102911226B (zh) * 2011-08-03 2015-11-25 胡梨芳 硬脂酸红霉素类化合物物实体及其用途
WO2013019975A1 (en) 2011-08-03 2013-02-07 University Of Iowa Research Foundation Compositions and methods of treating cancer
US9180134B2 (en) 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
US9775855B2 (en) 2011-09-14 2017-10-03 Thomas J. Lewis Compositions comprising macrolide and tetracycline and their uses
WO2013130968A1 (en) 2012-03-01 2013-09-06 University Of Cincinnati Ros-activated compounds as selective anti-cancer therapeutics
WO2014036037A1 (en) 2012-08-28 2014-03-06 Annam Biosciences, Llc N-boc-dendrimers and their conjugates
US20150224169A1 (en) 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
US20140106004A1 (en) 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636329B2 (en) 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
CA3159085A1 (en) 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
MD4626C1 (ro) 2013-04-24 2019-11-30 Smart Brain Sro Derivaţi de tamoxifen pentru tratamentul afecţiunilor neoplazice, în special cu nivel înalt de proteină HER2
EP3016715A4 (en) 2013-07-01 2017-02-08 University Of Georgia Research Foundation, Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CN103536530A (zh) 2013-10-30 2014-01-29 王玉万 盐酸多西环素长效注射剂及制备方法
US20150231069A1 (en) 2014-02-20 2015-08-20 Pankaj Modi Oral formulations of chemotherapeutic agents
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
EP3154596A4 (en) 2014-06-10 2018-01-24 Institute for Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
EP3206674B1 (en) 2014-10-17 2020-03-18 Targeted Therapies Research and Consulting Centre Multi-ingredient pharmaceutical composition for use in cancer therapy
CN104352566A (zh) 2014-10-21 2015-02-18 河南牧翔动物药业有限公司 一种水包油型复方金霉素纳米乳
JP6439931B2 (ja) 2015-02-26 2018-12-19 大日本印刷株式会社 吸着搬送装置および吸着搬送方法
CN108136207A (zh) 2015-10-06 2018-06-08 红山生物医药有限公司 用于治疗癌症的联合疗法
CN105884633B (zh) 2016-05-07 2017-12-26 浙江大学 一种四环素硬脂酸嫁接物及其制备和应用
CN109843931A (zh) 2016-08-11 2019-06-04 昆士兰医学研究所理事会 免疫调节化合物
CN106511317A (zh) 2016-12-13 2017-03-22 浙江中同科技有限公司 一种掩味克拉霉素颗粒的制备方法
EP3570856A2 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
EP3570857A1 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018195446A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
RU2019142102A (ru) 2017-05-19 2021-06-21 Лунелла Байотек, Инк. Антимитосцины: направленные ингибиторы митохондриального биогенеза для эрадикации злокачественных стволовых клеток
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
WO2018218242A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Methods and compositions for combination therapy
JP7066847B2 (ja) 2017-11-24 2022-05-13 ルネラ・バイオテック・インコーポレーテッド がん幹細胞を根絶するトリフェニルホスホニウム誘導体化合物
EP3728300A4 (en) 2017-12-20 2021-08-11 Lunella Biotech, Inc. TARGETING MITOCHONDRIAL FISSION VIA MDIVI-1 DERIVATIVES

Also Published As

Publication number Publication date
RU2019142102A (ru) 2021-06-21
ZA202202712B (en) 2023-11-29
AU2018270129A1 (en) 2020-01-16
WO2018213751A1 (en) 2018-11-22
BR112019024264A2 (pt) 2020-06-02
CU20190092A7 (es) 2020-10-20
JP6938682B2 (ja) 2021-09-22
ECSP19082194A (es) 2019-11-30
EP3624840A1 (en) 2020-03-25
RU2019142102A3 (es) 2021-06-21
EP3624840A4 (en) 2021-03-10
KR20200010343A (ko) 2020-01-30
JP2020527127A (ja) 2020-09-03
CN111315400A (zh) 2020-06-19
CA3063717A1 (en) 2018-11-22
AU2018270129B2 (en) 2021-01-07
ZA202102509B (en) 2023-03-29
IL270598B (en) 2022-04-01
US11160821B2 (en) 2021-11-02
MX2019013735A (es) 2020-01-15
ZA201907654B (en) 2022-07-27
NZ760422A (en) 2023-11-24
US20200179424A1 (en) 2020-06-11
CO2019012888A2 (es) 2020-05-15
US20220072020A1 (en) 2022-03-10
DOP2019000294A (es) 2020-02-16
CA3063717C (en) 2021-08-24
CR20190524A (es) 2020-01-10
PE20200605A1 (es) 2020-03-10
US11865130B2 (en) 2024-01-09

Similar Documents

Publication Publication Date Title
CL2019003283A1 (es) Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas.
CO2018003168A2 (es) Moduladores de la expresión de kras
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
BR112017000301A2 (pt) tratamento de leucemia com inibidores de histona desacetilase
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
GT201400043A (es) Imidazopiridazinas sustituidas con amino
UY38160A (es) Partículas implantables y métodos relacionados
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
BR112016024573A2 (pt) composições para deposição sobre superfícies biológicas
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
ECSP20082339A (es) Moduladores de la expresión de apol1
CY1122457T1 (el) Μη πτητικες οφθαλμικες συνθεσεις, ειδικες για τη θεραπεια της ξηροφθαλμιας